CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0566 (clinicaltrials.gov NCT No: NCT02006485)
Title:A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor, in Patients with B-cell Malignancies
Principal Investigator:Susan O'Brien
Treatment Agent:TGR-1202; Ublituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of the combination of ublituximab and TGR-1202 that can be given to patients
with B-cell lymphoma. The safety of this study drug combination will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I
Treatment Agents:TGR-1202
Ublituximab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:TG Therapeutics, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Susan O'Brien
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults